A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy

Relapsed and/or Refractory Multiple Myeloma Clinical Trial

Official title:

An Open-label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03416374
• Other study ID #: C16043
• Secondary ID: U1111-1207-0061J
• Status: Completed
• Phase: Phase 4
• Start date: February 18, 2018
• Est. completion date: May 28, 2021

Study information

• Verified date: May 2022
• Source: Takeda
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to investigate the efficacy and safety of long-term administration of the oral proteasome inhibitor ixazomib as part of ixazomib in combination with lenalidomide and dexamethasone (IRd) therapy in patients with relapsed and/or refractory multiple myeloma (RRMM) treated initially with an injectable proteasome inhibitor-based therapy.

Description:

The drug being tested in this study is called Ixazomib. Ixazomib is being tested to treat people who have RRMM. This study will look at the effectiveness and safety of IRd in participants with RRMM previously receiving an injectable proteasome inhibitor-based therapy. This study consists of two treatment periods, Treatment Period I and Treatment Period II.

The study will enroll 47 patients. All participants will receive following treatment:

• Combination therapy with Bortezomib + Lenalidomide + Dexamethasone (VRd) or combination therapy with Carfilzomib + Lenalidomide + Dexamethasone (KRd), standard recommended dose according to the package insert of each drug, as Treatment Period I, followed by Combination therapy with Ixazomib 4.0 mg + Lenalidomide 25 mg + Dexamethasone 40 mg (IRd) as Treatment Period II

At start of this study, combination therapy of VRd or KRd will be decided by investigator as Treatment Period I after the baseline evaluations. After the start of Treatment Period I, a participant's eligibility for Treatment Period II is then determined 3 cycles. Participants who meet these eligibility criteria II subsequently continue into Treatment Period II and receive IRd.

This multi-center trial will be conducted in Japan. It is anticipated that the treatment phase of this study will last up to 39 months, including 18 months for enrollment. Participants will make multiple visits to the clinic in treatment period, and follow-up period including a follow-up assessment after last dose of study drug.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 45
• Est. completion date: May 28, 2021
• Est. primary completion date: May 28, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

Eligibility for Treatment Period I

1. Men and women of age 20 years or older at the time of enrollment.

2. Participants with RRMM.

3. Participants who are planned to start combination therapy with bortezomib, lenalidomide, and dexamethasone (VRd) or carfilzomib, lenalidomide, and dexamethasone (KRd) as second, third or fourth line of treatment.

4. Participants with measurable disease defined by one or more of the following three measurements.

• Serum M-protein: =0.5 gram (g)/ deciliter (dL) (= 5 g/ liter [L])

• Urine M-protein: = 200 milligram (mg)/24 hours

• Serum free light chain assay: involved free light chain concentration = 10 mg/dL (= 100 mg/L) provided that the serum free light chain ratio is abnormal

5. Participants with Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2; however, participants with ECOG PS 3 are eligible if they only have symptoms associated with bone lesions.

6. Participants who are considered by the principal investigator or investigator not to be eligible for transplant; or, if considered eligible for transplant, participants who are planned not to undergo transplant for at least 12 months after the start of the study treatment.

7. Participants must be registered with, and comply with, the guidelines of the lenalidomide management program.

8. Participants who, before implementing procedures related to clinical research (excluding standard medical practices), understand that they can withdraw consent at any time without suffering from disadvantages to future treatments, and can provide written informed consent.

Eligibility for Treatment Period II

9. Participants must have received an injectable proteasome inhibitor (bortezomib or carfilzomib) in each treatment cycle of Treatment Period I.

Exclusion Criteria:

Eligibility for Treatment Period I

1. Women who are nursing or pregnant.

2. Participants with another active malignancy, i.e. synchronous active malignancy or previous malignancy with a disease-free period of less than 5 years, except for participants with carcinoma in situ (intraepithelial carcinoma) or intramucosal carcinoma judged to be cured by topical treatment.

3. Participants with poorly controlled active thrombosis.

4. Participants who have participated in a clinical trial of ixazomib or have been treated with ixazomib.

5. Participants who were refractory to either treatment regimen based on lenalidomide and/or proteasome inhibitor(s).

Note: Refractory MM is defined as PD on therapy or PD within 60 days after the last dose of a given therapy. Participants who have disease progressed 60 days after the last dose of a given therapy will be considered as relapsed in this study.

6. Participants with ongoing or active systemic infection, known hepatitis B virus infection, known hepatitis C virus infection, or known positivity to human immunodeficiency virus (HIV).

7. Participants who underwent major surgery within 14 days prior to enrollment to Treatment Period I. Surgery for bone lesions is not considered as major surgery.

8. Participants who received radiation therapy within 14 days prior to enrollment to Treatment Period I. If the radiation field is small, 7 days is considered as a sufficient interval between radiation therapy and chemotherapy.

9. Participants who experience Grade 1 peripheral neuropathy accompanied by pain, or Grade =2 peripheral neuropathy.

10. Evidence of current uncontrolled cardiovascular conditions, including uncontrolled hypertension, uncontrolled cardiac arrhythmia, symptomatic congestive heart failure, unstable angina, or myocardial infarction within the past 6 months before enrollment to Treatment Period I.

11. Infection requiring systemic antibiotic therapy or other serious infection within 14 days before enrollment into Treatment Period I.

12. Participants with central nervous system involvement.

13. Inability to swallow oral medications, inability or unwillingness to comply with the drug administration requirements, or gastrointestinal conditions that could interfere with the oral absorption or tolerance of treatment.

14. Psychiatric illness/social situation that would limit compliance with study requirements.

15. Comorbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the participant inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens.

Eligibility for Treatment Period II

16. Participants who do not achieve at least a minimal response (MR) to VRd or KRd in Treatment Period I per the International Myeloma Working Group (IMWG) response criteria, 2014 revision.

17. Participants who experience Grade 1 peripheral neuropathy accompanied by pain, or Grade =2 peripheral neuropathy during Treatment Period I.

18. Participants with evidence of uncontrolled cardiovascular conditions, including uncontrolled hypertension, uncontrolled cardiac arrhythmia, symptomatic congestive heart failure, unstable angina, or myocardial infarction during Treatment Period I.

19. Participants using potent CYP3A4 inducing agents (rifampicin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or gingko biloba or St. John's wort.

20. Participants with hypersensitivity to any of the IRd study medications, their analogs, or excipients contained in IRd.

21. Comorbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the participant inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens.

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell
• Relapsed and/or Refractory Multiple Myeloma

Intervention

Drug:
• Ixazomib
Ixazomib capsules
• Bortezomib
Bortezomib injections
• Carfilzomib
Carfilzomib intravenous infusions
• Lenalidomide
Lenalidomide capsules
• Dexamethasone
Dexamethasone tablets

Locations

Country	Name	City	State
Japan	Juntendo University Hospital	Bunkyo-ku	Tokyo
Japan	Nippon Medical School Hospital	Bunkyo-ku	Tokyo
Japan	Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital	Hiroshima
Japan	Nihon University Itabashi Hospital	Itabashi-ku	Tokyo
Japan	Kameda Medical Center	Kamogawa	Chiba
Japan	Kanazawa University Hospital	Kanazawa	Ishikawa
Japan	The Jikei University Kashiwa Hospital	Kashiwa	Chiba
Japan	Kobe city Medical Center General Hospital	Kobe	Hyogo
Japan	Dokkyo Medical University	Koshigaya	Saitama
Japan	The Cancer Institute Hospital of JFCR	Koto-ku	Tokyo
Japan	Kyoto Kuramaguchi Medical Center	Kyoto
Japan	Gunma University Hospital	Maebashi	Gunma
Japan	The Jikei University Hospital	Minato-ku	Tokyo
Japan	Kyorin University Hospital	Mitaka	Tokyo
Japan	Iwate Medical University	Morioka	Iwate
Japan	Niigata Cancer Center Hospital	Niigata
Japan	Ogaki Municipal Hospital	Ogaki	Gifu
Japan	Osaka Red Cross Hospital	Osaka
Japan	Shibukawa Medical Center	Shibukawa	Gunma
Japan	Japanese Red Cross Medical Center	Shibuya-ku	Tokyo
Japan	Suwa Red Cross Hospital	Suwa	Nagano
Japan	Tokyo Disaster Medical Center	Tachikawa	Tokyo
Japan	Yokohama Municipal Citizen's Hospital	Yokohama	Kanagawa

Sponsors (1)

Lead Sponsor	Collaborator
Takeda

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-Free Survival (PFS) Rate at 12 Months From the Start of Study Treatment	PFS rate was defined as the percentage of participants who were alive and have not had disease progression at 12 months after the date of first dose of treatment in Treatment Period I. PFS was assessed by International Myeloma Working Group (IMWG) Criteria (2014 version). Per IMWG criteria, progressive disease (PD): serum M-component increase =0.5 g/dl or urine M-component increase =200 mg/24-hour/ difference between involved and uninvolved free light chain (FLC) levels increase >10 mg/dl or bone marrow plasma cell =10%/ development of new/ increase in size of existing bone lesions or soft tissue plasmacytoma or development of hypercalcemia.	Up to 12 months
Secondary	Overall Survival (OS) From the Start of Study Treatment	OS was defined as the period from the first dose of treatment in Treatment Period I to the time when death (regardless of the cause of death) was confirmed. Participants who were still alive were censored at the last confirmed date of survival or the date of data cut-off, whichever was earlier.	Up to 39 months as a maximum
Secondary	PFS From the Start of Study Treatment	PFS was defined as the period from the first dose of treatment in Treatment Period I to the time of confirmed PD or confirmed death (regardless of the cause of death), whichever is earlier. PFS was assessed by IMWG Criteria.	Up to 39 months as a maximum
Secondary	Percentage of Participants Who Achieved VGPR or Better (CR + VGPR)	VGPR or better (CR + VGPR) were assessed by IMWG Criteria. Per IMWG criteria, PR (partial response): =50% reduction of serum M protein+reduction in 24-hour urinary M protein by =90%/ to <200 mg/24-hour or =50% decrease in difference between involved and uninvolved free light chain (FLC) levels/ =50% reduction in bone marrow plasma cells, if =30% at baseline/ =50% reduction in size of soft tissue plasmacytomas. VGPR (very good PR): serum+urine M-protein detectable by immunofixation but not on electrophoresis/ =90% reduction in serum M-protein+urine Mprotein level <100 mg/24-hour. CR (complete response): negative immunofixation on serum+urine+disappearance of soft tissue plasmacytomas+<5% plasma cells in bone marrow.	Up to 39 months as a maximum
Secondary	Number of Participants With Minimal Residual Disease (MRD) Positive or Negative in Bone Marrow in Participants Who Achieved CR	MRD was measured by the flow cytometry method using bone marrow aspiration. Reported data were numbers of participants with MRD positive and negative in bone marrow in participants who achieved CR. MRD positive was categorized into three sensitivity levels with the numbers of cells counted (10^-4 to - Max; 10^-5 to 10^-4; 10^-6 to 10^-5). MRD negativity is defined as absence of MRD and MRD positivity is defined as presence of MRD. If a participant is MRD-positive at their first evaluation and MRD-negative after re-examination, the participant will be considered to be MRD-negative. CR will be assessed by IMWG Criteria.	Up to 39 months as a maximum
Secondary	Percentage of Participants Who Achieve or Maintain Any Best Response	Best response is defined as the cumulative numbers of participants who achieve each level of best response including PR, VGPR and CR assessed with IMWG Criteria, after each cycle of treatment. Per IMWG criteria, PR (partial response): =50% reduction of serum M protein+reduction in 24-hour urinary M protein by =90%/ to <200 mg/24-hour or =50% decrease in difference between involved and uninvolved free light chain (FLC) levels/ =50% reduction in bone marrow plasma cells, if =30% at baseline/ =50% reduction in size of soft tissue plasmacytomas. VGPR (very good PR): serum+urine M-protein detectable by immunofixation but not on electrophoresis/ =90% reduction in serum M-protein+urine Mprotein level <100 mg/24-hour. CR (complete response): negative immunofixation on serum+urine+disappearance of soft tissue plasmacytomas+<5% plasma cells in bone marrow.	Up to 39 months as a maximum
Secondary	Overall Response Rate (ORR)	ORR is defined as the percentage of participants who achieve a best response of PR or better including stringent complete response (sCR), VGPR and PR assessed with IMWG Criteria, after the start of the study treatment. Per IMWG criteria, PR (partial response): =50% reduction of serum M protein+reduction in 24-hour urinary M protein by =90%/ to <200 mg/24-hour or =50% decrease in difference between involved and uninvolved free light chain (FLC) levels/ =50% reduction in bone marrow plasma cells, if =30% at baseline/ =50% reduction in size of soft tissue plasmacytomas. VGPR (very good PR): serum+urine M-protein detectable by immunofixation but not on electrophoresis/ =90% reduction in serum M-protein+urine Mprotein level <100 mg/24-hour. CR (complete response): negative immunofixation on serum+urine+disappearance of soft tissue plasmacytomas+<5% plasma cells in bone marrow.	Up to 39 months as a maximum
Secondary	Percentage of Participants Continuing Treatment With Ixazomib at 12 Months From the Start of Study Treatment		12 months
Secondary	Duration of Response (DOR)	DOR is defined as the time from the date of first documentation of response =PR to the date of first documentation of PD or death due to any cause. PR and PD will be assessed with IMWG Criteria. Per IMWG criteria, PR (partial response): =50% reduction of serum M protein+reduction in 24-hour urinary M protein by =90%/ to <200 mg/24-hour or =50% decrease in difference between involved and uninvolved free light chain (FLC) levels/ =50% reduction in bone marrow plasma cells, if =30% at baseline/ =50% reduction in size of soft tissue plasmacytomas. VGPR (very good PR): serum+urine M-protein detectable by immunofixation but not on electrophoresis/ =90% reduction in serum M-protein+urine Mprotein level <100 mg/24-hour. CR (complete response): negative immunofixation on serum+urine+disappearance of soft tissue plasmacytomas+<5% plasma cells in bone marrow.	Up to 39 months as a maximum
Secondary	Time to Next Treatment (TTNT)	TTNT is defined as the period from the start of study treatment Period I to the start of next line treatment.	Up to 39 months as a maximum
Secondary	Duration of Therapy (DOT)	DOT is defined as the treatment duration of study drug at study treatment Period I.	Up to 39 months as a maximum
Secondary	Patient-Reported Outcome Health-Related Quality of Life (HRQoL) Based on Global Health Status Scale of European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-C30 (EORTC QLQ-C30)	EORTC QLQ-C30 contains 30 items across 5 functional scales (physical, role, cognitive, emotional, and social), 9 symptom scales (fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and financial difficulties) and a global health status/QOL scale (Global Health Status). EORTC QLQ-C30 contains 28 questions (4-point scale where 1=Not at all [best] to 4=Very Much [worst]) and 2 questions (7-point scale where 1=Very poor [worst] to 7= Excellent [best]). Raw scores are converted into scale scores ranging from 0 to 100. For the functional scales and the global health status/QOL scale, higher scores represent better QOL; for the symptom scales, lower scores represent better QOL.	Baseline and End of Treatment (Up to 23 cycles for VRd Group, Up to 32 cycles for KRd and Overall Group, each cycle was of 28 days)
Secondary	Patient-Reported Outcome HRQoL Based on EORTC Multiple Myeloma Module (EORTC QLQ-MY20) Score	EORTC QLQ-MY20 has 20 items across 4 independent subscales, 2 functional subscales (body image, future perspective), and 2 symptoms scales (disease symptoms, and side effects of treatment). Scores are averaged, and transformed to 0-100 scale. For the functional scales, high scores represent improvement. For the symptom scales, higher scores represent worsening.	Baseline and End of Treatment (Up to 23 cycles for VRd Group, Up to 32 cycles for KRd and Overall Group, each cycle was of 28 days)
Secondary	Evaluation of Modified Quality-Adjusted Life-Years (QALYs)	Modified QALYs was calculated from the score of EORTC QLQ-C30. The health-related quality of life scale score of EORTC QLQ-C30 was converted into a utility value ranging from 0 (dead) to 1 (perfect health), and used to adjust the value of survival years; this value was assessed as the modified QALY.	Up to 39 months as a maximum
Secondary	Healthcare Resource Utilization (HCRU): Number of Events With Hospitalization Per Participants-Month	HCRU was calculated from Exposure-adjusted rate of hospitalization events (per participants-months) and the duration of hospitalization among participants in Treatment Period I and Treatment Period II. Number of events with hospitalization per participants-month in Treatment Period I and Treatment Period II was reported.	Up to 39 months as a maximum
Secondary	Healthcare Resource Utilization (HCRU): Duration of Hospital Stay Per Participants	HCRU was calculated from Exposure-adjusted rate of hospitalization events (per participants-months) and the duration of hospitalization among participants in Treatment Period I and Treatment Period II. Duration of hospital stay per participants in Treatment Period I and Treatment Period II was reported.	Up to 39 months as a maximum
Secondary	Relative Dose Intensity (RDI)	RDI for each study drug is defined as 100*(Total amount of dose taken)/(Total prescribed dose of treated cycles), where total prescribed dose equals [dose prescribed at enrollment* number of prescribed doses per cycle* the number of treated cycles].	Up to 39 months as a maximum
Secondary	Percentage of Participants With Bone Lesions (Bone Evaluation)		Up to 39 months as a maximum
Secondary	Number of Participants Reporting One or More Treatment-Emergent AEs (TEAEs)	An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug.	Up to 39 months as a maximum

External Links

•   To obtain more information on the study, click here/on this link